Cargando…
Vaccines for immunoprevention of DNA mismatch repair deficient cancers
The development of cancer vaccines to induce tumor-antigen specific immune responses was sparked by the identification of antigens specific to or overexpressed in cancer cells. However, weak immunogenicity and the mutational heterogeneity in many cancers have dampened cancer vaccine successes. With...
Autores principales: | Hernandez-Sanchez, Alejandro, Grossman, Mark, Yeung, Kevin, Sei, Shizuko S, Lipkin, Steven, Kloor, Matthias |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9226910/ https://www.ncbi.nlm.nih.gov/pubmed/35732349 http://dx.doi.org/10.1136/jitc-2021-004416 |
Ejemplares similares
-
Lynch syndrome cancer vaccines: A roadmap for the development of precision immunoprevention strategies
por: Sei, Shizuko, et al.
Publicado: (2023) -
Immunoprevention of KRAS-driven lung adenocarcinoma by a multipeptide vaccine
por: Pan, Jing, et al.
Publicado: (2017) -
Molecular models for the tissue specificity of DNA mismatch repair-deficient carcinogenesis
por: Chao, Elizabeth C., et al.
Publicado: (2006) -
Organoids and metastatic orthotopic mouse model for mismatch repair-deficient colorectal cancer
por: Song, Yurong, et al.
Publicado: (2023) -
Targeting Glutamine Metabolism to Enhance Immunoprevention of EGFR‐Driven Lung Cancer
por: Huang, Mofei, et al.
Publicado: (2022)